Ramucirumab biosimilar (CTTQ)

雷莫芦单抗生物类似药（正大天晴）

Report date: 2025/05/01 20:00:06

Base Information

Drug NameRamucirumab biosimilar (CTTQ)
Drug Alias Name雷莫芦单抗生物仿制药（正大天晴）雷莫西尤单抗生物类似药（正大天晴）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms

Other Information

ATC CodeL01XC21
Related LinksN/A